|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 59 | 26/09/2017 | |
Bruno Schick
BRD | Director/Board Member | - | 26/09/2017 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +1.81% | +2.25% | +13.55% | +81.13% | 47.15B | ||
| -2.54% | +4.24% | +63.60% | +114.38% | 37.94B | ||
| +0.15% | +1.26% | -2.63% | +43.67% | 12.35B | ||
| +3.71% | +3.56% | +14.59% | +95.63% | 11.52B | ||
| +1.75% | -1.34% | +33.25% | +122.84% | 8.93B | ||
| +0.66% | +0.41% | +23.13% | +44.77% | 7.14B | ||
| +0.71% | +3.35% | +54.96% | -7.18% | 7.02B | ||
| +0.68% | +2.63% | +24.92% | +227.07% | 6.51B | ||
| +9.99% | +27.85% | -16.33% | +28.50% | 5.98B | ||
| Average | +1.69% | +3.43% | +23.23% | +83.43% | 15.03B | |
| Weighted average by Cap. | +0.82% | +3.07% | +28.36% | +88.70% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















